BioRestorative Therapies, Inc. Key Metrics

2 years of history · ending 2025-12-31 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-2
Book Value Per Share
$0
Free Cash Flow Per Share
$-1
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-1
Return on Equity
-320.5%
Return on Assets
-174.1%
Return on Invested Capital
-278.2%
Debt to Equity
Current Ratio
0.84
Quick Ratio
0.84
Asset Turnover
0.04
Days Sales Outstanding
15.73
Days Payables Outstanding
20535.38
Days Inventory On Hand
Cash Conversion Cycle
R&D / Revenue
2806.4%
SBC / Revenue
924.6%
Capex / Revenue
32.3%
Working Capital
$-586K
Net Current Asset Value
$3M
Invested Capital
$357K
OCF / Net Income
0.76
FCF / Net Income
0.77
Accruals Ratio (Sloan)
-84.6%
Net Debt
$-3M
Net Debt / EBITDA
0.19
Interest Coverage
Cash Coverage
Capex Coverage
-92.95
Tangible Common Equity
$-177K
TCE / Total Assets
-4.3%
NOPAT
$-12M
Cash ROIC
-245.4%
WC / Revenue
-162.9%
Capex / D&A
0.55
Reinvestment Rate
0.6%
Total Payout Ratio
0.0%
Asset Growth vs Revenue Growth
-56.5%
Revenue 5Y CAGR
36.1%
Stock Price (FY-end)
$1
Market Cap
$11M
P/S Ratio
29.38
P/B Ratio
29.62
P/TB Ratio
1.40
Enterprise Value
$8M
EV / Sales
21.17
FCF Yield
-103.2%
Shareholder Yield
-31.5%
Buyback Yield
0.0%
R&D Yield
95.5%
Capex Yield
1.1%
Shares Variation (YoY)
15.8%
Beta (5Y)
1.04
Cost of Equity
9.7%
Cost of Debt (after tax)
52W High
$2
52W Low
$1
Trailing Return 1Y
-24.2%
Trailing Return 5Y
-96.5%
F-Score (Piotroski)
3.00
Z-Score (Altman)
-18.32

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

BioRestorative Therapies, Inc. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes-5.00%5.60%7.80%1.70%0.00%0.00%
Foreign Rate Differential0.00%
Other Adjustments7.60%-8.90%7.80%7.20%1.00%0.40%
SBC (Nondeductible)-43.40%
Valuation Allowance Change18.40%-17.70%-44.00%-29.70%39.70%20.40%
Tax Law Change
Effective Tax Rate0.00%0.00%0.00%0.00%0.00%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)
Income Taxes Paid (Cash)